Kodiak Sciences Inc.

Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing therapeutics for retinal diseases. The company's lead candidate, tarcocimab tedromer (KSI-301), is an anti-VEGF antibody biopolymer currently in Phase 3 clinical trials for multiple indications including diabetic retinopathy, wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. KSI-301 has completed Phase 3 testing for high-prevalence retinal vascular diseases. The company is also advancing a pipeline of preclinical and early-stage programs, including KSI-501, a bispecific antibody targeting both interleukin-6 and VEGF, and KSI-101, an unconjugated bispecific protein with the same targets designed for patients presenting with retinal fluid and inflammation.

As a clinical-stage entity, Kodiak Sciences generates no material revenue from product sales. The company operates with approximately 123 full-time employees and is headquartered in Palo Alto, California. Founded in 2009 under the original name Oligasis LLC, the company rebranded to Kodiak Sciences in 2015. It is incorporated in Delaware and trades on Nasdaq with a market capitalization of approximately $1.6 billion.